These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 16135655)
21. Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics. Balf G Am J Psychiatry; 2008 Sep; 165(9):1206-7; author reply 1207. PubMed ID: 18765500 [No Abstract] [Full Text] [Related]
22. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Vieweg WV; Sood AB; Pandurangi A; Silverman JJ Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101 [TBL] [Abstract][Full Text] [Related]
23. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Bishop JR; Ellingrod VL; Moline J; Miller D Med Sci Monit; 2006 Feb; 12(2):BR47-50. PubMed ID: 16449941 [TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain. Godlewska BR; Olajossy-Hilkesberger L; Olajossy M; Limon J; Landowski J J Clin Psychopharmacol; 2013 Jun; 33(3):436-7. PubMed ID: 23609395 [No Abstract] [Full Text] [Related]
26. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. Koga M; Nakayama K Acta Psychiatr Scand; 2005 Jul; 112(1):75-6; discussion 77. PubMed ID: 15952949 [TBL] [Abstract][Full Text] [Related]
27. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209 [TBL] [Abstract][Full Text] [Related]
28. Modelling olanzapine-induced weight gain in rats. van der Zwaal EM; Janhunen SK; la Fleur SE; Adan RA Int J Neuropsychopharmacol; 2014 Jan; 17(1):169-86. PubMed ID: 24103788 [TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with atypical antipsychotics and risk of weight gain. Stip E; Anselmo K; Wolfe M; Lessard C; Landry P Drug Saf; 2006; 29(6):550-2; author reply 552. PubMed ID: 16752937 [No Abstract] [Full Text] [Related]
33. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine". Reis de Sá A; Elkis H Braz J Psychiatry; 2007 Mar; 29(1):90; author reply 91. PubMed ID: 17435940 [No Abstract] [Full Text] [Related]
34. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Kim JH; Yim SJ; Nam JH Schizophr Res; 2006 Feb; 82(1):115-7. PubMed ID: 16326074 [No Abstract] [Full Text] [Related]
35. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Baptista T; Martinez M; Lacruz A; Arellano A; Mendoza S; Beaulieu S; Hernández L; Contreras Q; Galeazzi T; Vargas D Schizophr Res; 2007 Jan; 89(1-3):350-2. PubMed ID: 17029751 [No Abstract] [Full Text] [Related]
36. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain. Atmaca M; Tezcan E; Ustundag B J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639 [TBL] [Abstract][Full Text] [Related]
37. Interventions to reduce weight gain in schizophrenia. Faulkner G; Cohn T; Remington G Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900 [No Abstract] [Full Text] [Related]
38. Cognitive behavior therapy for weight gain. Umbricht D; Flury H; Bridler R Am J Psychiatry; 2001 Jun; 158(6):971. PubMed ID: 11384925 [No Abstract] [Full Text] [Related]